SWOG 8825: Melphalan GM-CSF: A phase I study

Elizabeth Poplin, Harriet O. Smith, Brent Behrens, Bruce Redman, Lawrence Flaherty, James Neidhart, David Alberts

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The use of intravenous melphalan at higher doses is limited by severe myelosuppression. It was postulated that GM-CSF would permit the use of higher dose melphalan with only moderate myelosuppression easily manageable in an outpatient setting. Therefore, a phase I study of intravenous melphalan utilizing GM-CSF (recombinant granulocyte-macrophage colony-stimulating factor) support was initiated. Intravenous melphalan at doses of 15-45 mg/m2 was administered every 28 days. GM-CSF was utilized at doses of 10-20 μg/kg/day subcutaneously Days 2-21 on a 28-day cycle. Twenty-five patients received 53 courses of therapy. The dose-limiting toxicities were severe or life-threatening granulocytopenia and thrombocytopenia. Utilizing 20 μg/kg/day GM-CSF, the maximum tolerated dose (MTD) of melphalan is 30 mg/m2 and, with 10 mg/kg/day GM-CSF, the maximum tolerated melphalan dose is only 20 mg/m2. One patient with ovarian cancer achieved a partial response. Because the reported MTD of intravenous melphalan without GM-CSF is 30 mg/m2, GM-CSF has not allowed sufficient escalation of the intravenous melphalan dose for routine outpatient use.

Original languageEnglish (US)
Pages (from-to)66-70
Number of pages5
JournalGynecologic Oncology
Volume44
Issue number1
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Melphalan
Granulocyte-Macrophage Colony-Stimulating Factor
Maximum Tolerated Dose
Outpatients
Agranulocytosis
Thrombocytopenia
Ovarian Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Poplin, E., Smith, H. O., Behrens, B., Redman, B., Flaherty, L., Neidhart, J., & Alberts, D. (1992). SWOG 8825: Melphalan GM-CSF: A phase I study. Gynecologic Oncology, 44(1), 66-70. https://doi.org/10.1016/0090-8258(92)90014-A

SWOG 8825 : Melphalan GM-CSF: A phase I study. / Poplin, Elizabeth; Smith, Harriet O.; Behrens, Brent; Redman, Bruce; Flaherty, Lawrence; Neidhart, James; Alberts, David.

In: Gynecologic Oncology, Vol. 44, No. 1, 1992, p. 66-70.

Research output: Contribution to journalArticle

Poplin, E, Smith, HO, Behrens, B, Redman, B, Flaherty, L, Neidhart, J & Alberts, D 1992, 'SWOG 8825: Melphalan GM-CSF: A phase I study', Gynecologic Oncology, vol. 44, no. 1, pp. 66-70. https://doi.org/10.1016/0090-8258(92)90014-A
Poplin E, Smith HO, Behrens B, Redman B, Flaherty L, Neidhart J et al. SWOG 8825: Melphalan GM-CSF: A phase I study. Gynecologic Oncology. 1992;44(1):66-70. https://doi.org/10.1016/0090-8258(92)90014-A
Poplin, Elizabeth ; Smith, Harriet O. ; Behrens, Brent ; Redman, Bruce ; Flaherty, Lawrence ; Neidhart, James ; Alberts, David. / SWOG 8825 : Melphalan GM-CSF: A phase I study. In: Gynecologic Oncology. 1992 ; Vol. 44, No. 1. pp. 66-70.
@article{a1c00333392f4b94a66ae88b4a0acd03,
title = "SWOG 8825: Melphalan GM-CSF: A phase I study",
abstract = "The use of intravenous melphalan at higher doses is limited by severe myelosuppression. It was postulated that GM-CSF would permit the use of higher dose melphalan with only moderate myelosuppression easily manageable in an outpatient setting. Therefore, a phase I study of intravenous melphalan utilizing GM-CSF (recombinant granulocyte-macrophage colony-stimulating factor) support was initiated. Intravenous melphalan at doses of 15-45 mg/m2 was administered every 28 days. GM-CSF was utilized at doses of 10-20 μg/kg/day subcutaneously Days 2-21 on a 28-day cycle. Twenty-five patients received 53 courses of therapy. The dose-limiting toxicities were severe or life-threatening granulocytopenia and thrombocytopenia. Utilizing 20 μg/kg/day GM-CSF, the maximum tolerated dose (MTD) of melphalan is 30 mg/m2 and, with 10 mg/kg/day GM-CSF, the maximum tolerated melphalan dose is only 20 mg/m2. One patient with ovarian cancer achieved a partial response. Because the reported MTD of intravenous melphalan without GM-CSF is 30 mg/m2, GM-CSF has not allowed sufficient escalation of the intravenous melphalan dose for routine outpatient use.",
author = "Elizabeth Poplin and Smith, {Harriet O.} and Brent Behrens and Bruce Redman and Lawrence Flaherty and James Neidhart and David Alberts",
year = "1992",
doi = "10.1016/0090-8258(92)90014-A",
language = "English (US)",
volume = "44",
pages = "66--70",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - SWOG 8825

T2 - Melphalan GM-CSF: A phase I study

AU - Poplin, Elizabeth

AU - Smith, Harriet O.

AU - Behrens, Brent

AU - Redman, Bruce

AU - Flaherty, Lawrence

AU - Neidhart, James

AU - Alberts, David

PY - 1992

Y1 - 1992

N2 - The use of intravenous melphalan at higher doses is limited by severe myelosuppression. It was postulated that GM-CSF would permit the use of higher dose melphalan with only moderate myelosuppression easily manageable in an outpatient setting. Therefore, a phase I study of intravenous melphalan utilizing GM-CSF (recombinant granulocyte-macrophage colony-stimulating factor) support was initiated. Intravenous melphalan at doses of 15-45 mg/m2 was administered every 28 days. GM-CSF was utilized at doses of 10-20 μg/kg/day subcutaneously Days 2-21 on a 28-day cycle. Twenty-five patients received 53 courses of therapy. The dose-limiting toxicities were severe or life-threatening granulocytopenia and thrombocytopenia. Utilizing 20 μg/kg/day GM-CSF, the maximum tolerated dose (MTD) of melphalan is 30 mg/m2 and, with 10 mg/kg/day GM-CSF, the maximum tolerated melphalan dose is only 20 mg/m2. One patient with ovarian cancer achieved a partial response. Because the reported MTD of intravenous melphalan without GM-CSF is 30 mg/m2, GM-CSF has not allowed sufficient escalation of the intravenous melphalan dose for routine outpatient use.

AB - The use of intravenous melphalan at higher doses is limited by severe myelosuppression. It was postulated that GM-CSF would permit the use of higher dose melphalan with only moderate myelosuppression easily manageable in an outpatient setting. Therefore, a phase I study of intravenous melphalan utilizing GM-CSF (recombinant granulocyte-macrophage colony-stimulating factor) support was initiated. Intravenous melphalan at doses of 15-45 mg/m2 was administered every 28 days. GM-CSF was utilized at doses of 10-20 μg/kg/day subcutaneously Days 2-21 on a 28-day cycle. Twenty-five patients received 53 courses of therapy. The dose-limiting toxicities were severe or life-threatening granulocytopenia and thrombocytopenia. Utilizing 20 μg/kg/day GM-CSF, the maximum tolerated dose (MTD) of melphalan is 30 mg/m2 and, with 10 mg/kg/day GM-CSF, the maximum tolerated melphalan dose is only 20 mg/m2. One patient with ovarian cancer achieved a partial response. Because the reported MTD of intravenous melphalan without GM-CSF is 30 mg/m2, GM-CSF has not allowed sufficient escalation of the intravenous melphalan dose for routine outpatient use.

UR - http://www.scopus.com/inward/record.url?scp=0026599287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026599287&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90014-A

DO - 10.1016/0090-8258(92)90014-A

M3 - Article

C2 - 1730428

AN - SCOPUS:0026599287

VL - 44

SP - 66

EP - 70

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -